FDA Greenlights First Twice-Yearly Biologic for Severe Eosinophilic Asthma
The U.S. Food and Drug Administration has granted approval to depemokimab, marketed as Exdensur, marking it as the inaugural ultra-long-acting biologic therapy administered just twice annually for individuals suffering from severe asthma exhibiting an eosinophilic profile. This milestone approval was…